25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AAPG (Ascentage) Stock Analysis
Buy, Hold or Sell?

Let's analyze Ascentage together

I guess you are interested in Ascentage Pharma Group International. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Ascentage’s Financial Insights
  • 📈 Technical Analysis (TA) – Ascentage’s Price Targets

I'm going to help you getting a better view of Ascentage Pharma Group International. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Ascentage Pharma Group International

I send you an email if I find something interesting about Ascentage Pharma Group International.

1. Quick Overview

1.1. Quick analysis of Ascentage (30 sec.)










1.2. What can you expect buying and holding a share of Ascentage? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.11
Expected worth in 1 year
$0.44
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
$0.33
Return On Investment
0.8%

For what price can you sell your share?

Current Price per Share
$42.85
Expected price per share
$23.06 - $
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Ascentage (5 min.)




Live pricePrice per Share (EOD)
$42.85
Intrinsic Value Per Share
$-0.99 - $3.36
Total Value Per Share
$-0.88 - $3.47

2.2. Growth of Ascentage (5 min.)




Is Ascentage growing?

Current yearPrevious yearGrowGrow %
How rich?$38.2m$9.8m$28.3m74.2%

How much money is Ascentage making?

Current yearPrevious yearGrowGrow %
Making money-$56.5m-$129.1m$72.5m128.3%
Net Profit Margin-41.3%-417.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Ascentage (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#444 / 881

Most Revenue
#73 / 881

Most Profit
#802 / 881

Most Efficient
#470 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Ascentage?

Welcome investor! Ascentage's management wants to use your money to grow the business. In return you get a share of Ascentage.

First you should know what it really means to hold a share of Ascentage. And how you can make/lose money.

Speculation

The Price per Share of Ascentage is $42.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ascentage.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ascentage, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.11. Based on the TTM, the Book Value Change Per Share is $0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ascentage.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.16-0.4%-0.16-0.4%-0.37-0.9%-0.30-0.7%-0.29-0.7%-0.25-0.6%
Usd Book Value Change Per Share0.080.2%0.080.2%-0.14-0.3%-0.13-0.3%-0.05-0.1%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.080.2%0.080.2%-0.14-0.3%-0.13-0.3%-0.05-0.1%0.010.0%
Usd Price Per Share0.00-0.00-0.00-0.00-0.00-0.00-
Price to Earnings Ratio0.00-0.00-0.00-0.00-0.00-0.00-
Price-to-Total Gains Ratio
Price to Book Ratio0.00-0.00-0.00-0.00-0.00-0.00-
Price-to-Total Gains Ratio

When do you get the money?

Usd Investment
$.00
Usd Price Per Share42.85
Number of shares23
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.08-0.05
Usd Total Gains Per Share0.08-0.05
Gains per Quarter (23 shares)1.88-1.14
Gains per Year (23 shares)7.50-4.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
108-20-5-15
201560-9-20
3023140-14-25
4030220-18-30
5038300-23-35
6045380-27-40
7053460-32-45
8060540-36-50
9068620-41-55
10075700-45-60

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.09.00.00.0%0.09.00.00.0%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%3.06.00.033.3%3.06.00.033.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.09.00.0%0.00.09.00.0%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%3.06.00.033.3%3.06.00.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Ascentage Pharma Group International compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0820.0820%-0.135+266%-0.128+257%-0.049+161%0.012+568%
Book Value Per Share--0.1100.1100%0.028+288%0.101+9%0.227-52%0.114-4%
Current Ratio--1.2641.2640%1.439-12%5.204-76%4.068-69%5.048-75%
Debt To Asset Ratio--0.8950.8950%0.972-8%0.908-1%0.763+17%0.905-1%
Debt To Equity Ratio--8.8718.8710%40.217-78%18.338-52%11.488-23%6.421+38%
Dividend Per Share----0%-0%-0%-0%-0%
Eps---0.162-0.1620%-0.371+128%-0.296+82%-0.294+81%-0.255+57%
Free Cash Flow Per Share---0.054-0.0540%-0.314+477%-0.242+345%-0.297+447%-0.210+287%
Free Cash Flow To Equity Per Share--0.0720.0720%-0.166+331%-0.068+194%0.033+117%0.053+34%
Gross Profit Margin--1.4831.4830%1.211+22%1.291+15%1.187+25%1.104+34%
Intrinsic Value_10Y_max--3.361----------
Intrinsic Value_10Y_min---0.986----------
Intrinsic Value_1Y_max---0.117----------
Intrinsic Value_1Y_min---0.250----------
Intrinsic Value_3Y_max---0.006----------
Intrinsic Value_3Y_min---0.624----------
Intrinsic Value_5Y_max--0.522----------
Intrinsic Value_5Y_min---0.858----------
Market Cap14923241292.800+100%--0%-0%-0%-0%-0%
Net Profit Margin---0.413-0.4130%-4.170+909%-2.931+609%-48.804+11705%-47.730+11445%
Operating Margin---0.337-0.3370%-3.770+1018%-2.610+674%-48.523+14284%-45.747+13462%
Operating Ratio--1.3771.3770%4.931-72%3.787-64%54.627-97%44.496-97%
Pb Ratio390.195+100%--0%-0%-0%-0%-0%
Pe Ratio-263.8580%--0%-0%-0%-0%-0%
Price Per Share42.850+100%--0%-0%-0%-0%-0%
Price To Free Cash Flow Ratio-788.6460%--0%-0%-0%-0%-0%
Quick Ratio--1.1851.1850%1.324-11%4.928-76%3.877-69%5.674-79%
Return On Assets---0.155-0.1550%-0.370+139%-0.279+80%-0.299+93%-0.377+143%
Return On Equity---1.535-1.5350%-15.321+898%-6.339+313%-4.090+167%-2.457+60%
Total Gains Per Share--0.0820.0820%-0.135+266%-0.128+257%-0.049+161%0.012+568%
Usd Book Value--38245599.00038245599.0000%9853164.000+288%35035518.000+9%79091199.000-52%39793088.000-4%
Usd Book Value Change Per Share--0.0820.0820%-0.135+266%-0.128+257%-0.049+161%0.012+568%
Usd Book Value Per Share--0.1100.1100%0.028+288%0.101+9%0.227-52%0.114-4%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Eps---0.162-0.1620%-0.371+128%-0.296+82%-0.294+81%-0.255+57%
Usd Free Cash Flow---18922617.000-18922617.0000%-109217479.500+477%-84139192.500+345%-103569961.500+447%-73141679.000+287%
Usd Free Cash Flow Per Share---0.054-0.0540%-0.314+477%-0.242+345%-0.297+447%-0.210+287%
Usd Free Cash Flow To Equity Per Share--0.0720.0720%-0.166+331%-0.068+194%0.033+117%0.053+34%
Usd Market Cap14923241292.800+100%--0%-0%-0%-0%-0%
Usd Price Per Share42.850+100%--0%-0%-0%-0%-0%
Usd Profit---56557903.500-56557903.5000%-129126361.500+128%-102950721.000+82%-102505269.600+81%-88759169.000+57%
Usd Revenue--136800675.000136800675.0000%30966768.000+342%65674042.500+108%39872519.480+243%22698782.211+503%
Usd Total Gains Per Share--0.0820.0820%-0.135+266%-0.128+257%-0.049+161%0.012+568%
 EOD+3 -2MRQTTM+0 -0YOY+24 -23Y+24 -25Y+20 -610Y+20 -6

3.3 Fundamental Score

Let's check the fundamental score of Ascentage Pharma Group International based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-263.858
Price to Book Ratio (EOD)Between0-1390.195
Net Profit Margin (MRQ)Greater than0-0.413
Operating Margin (MRQ)Greater than0-0.337
Quick Ratio (MRQ)Greater than11.185
Current Ratio (MRQ)Greater than11.264
Debt to Asset Ratio (MRQ)Less than10.895
Debt to Equity Ratio (MRQ)Less than18.871
Return on Equity (MRQ)Greater than0.15-1.535
Return on Assets (MRQ)Greater than0.05-0.155
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Ascentage Pharma Group International based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5079.809
Ma 20Greater thanMa 5035.238
Ma 50Greater thanMa 10029.035
Ma 100Greater thanMa 20024.311
OpenGreater thanClose41.500
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Ascentage Pharma Group International

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is also involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Fundamental data was last updated by Penke on 2025-06-27 23:03:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Ascentage earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Ascentage to the Biotechnology industry mean.
  • A Net Profit Margin of -41.3% means that $-0.41 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ascentage Pharma Group International:

  • The MRQ is -41.3%. The company is making a huge loss. -2
  • The TTM is -41.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-41.3%TTM-41.3%0.0%
TTM-41.3%YOY-417.0%+375.6%
TTM-41.3%5Y-4,880.4%+4,839.1%
5Y-4,880.4%10Y-4,773.0%-107.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-41.3%-91.7%+50.4%
TTM-41.3%-139.0%+97.7%
YOY-417.0%-194.4%-222.6%
3Y-293.1%-248.5%-44.6%
5Y-4,880.4%-343.3%-4,537.1%
10Y-4,773.0%-488.9%-4,284.1%
4.3.1.2. Return on Assets

Shows how efficient Ascentage is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ascentage to the Biotechnology industry mean.
  • -15.5% Return on Assets means that Ascentage generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ascentage Pharma Group International:

  • The MRQ is -15.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.5%TTM-15.5%0.0%
TTM-15.5%YOY-37.0%+21.5%
TTM-15.5%5Y-29.9%+14.4%
5Y-29.9%10Y-37.7%+7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.5%-11.6%-3.9%
TTM-15.5%-11.7%-3.8%
YOY-37.0%-11.4%-25.6%
3Y-27.9%-11.9%-16.0%
5Y-29.9%-12.1%-17.8%
10Y-37.7%-13.8%-23.9%
4.3.1.3. Return on Equity

Shows how efficient Ascentage is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ascentage to the Biotechnology industry mean.
  • -153.5% Return on Equity means Ascentage generated $-1.53 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ascentage Pharma Group International:

  • The MRQ is -153.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -153.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-153.5%TTM-153.5%0.0%
TTM-153.5%YOY-1,532.1%+1,378.6%
TTM-153.5%5Y-409.0%+255.5%
5Y-409.0%10Y-245.7%-163.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-153.5%-13.5%-140.0%
TTM-153.5%-15.0%-138.5%
YOY-1,532.1%-14.5%-1,517.6%
3Y-633.9%-16.9%-617.0%
5Y-409.0%-17.9%-391.1%
10Y-245.7%-19.9%-225.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Ascentage Pharma Group International.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Ascentage is operating .

  • Measures how much profit Ascentage makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ascentage to the Biotechnology industry mean.
  • An Operating Margin of -33.7% means the company generated $-0.34  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ascentage Pharma Group International:

  • The MRQ is -33.7%. The company is operating very inefficient. -2
  • The TTM is -33.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-33.7%TTM-33.7%0.0%
TTM-33.7%YOY-377.0%+343.2%
TTM-33.7%5Y-4,852.3%+4,818.5%
5Y-4,852.3%10Y-4,574.7%-277.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.7%-229.2%+195.5%
TTM-33.7%-249.7%+216.0%
YOY-377.0%-208.4%-168.6%
3Y-261.0%-221.7%-39.3%
5Y-4,852.3%-344.1%-4,508.2%
10Y-4,574.7%-470.4%-4,104.3%
4.3.2.2. Operating Ratio

Measures how efficient Ascentage is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.38 means that the operating costs are $1.38 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ascentage Pharma Group International:

  • The MRQ is 1.377. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.377. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.377TTM1.3770.000
TTM1.377YOY4.931-3.554
TTM1.3775Y54.627-53.250
5Y54.62710Y44.496+10.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3772.108-0.731
TTM1.3772.680-1.303
YOY4.9313.080+1.851
3Y3.7873.621+0.166
5Y54.6274.734+49.893
10Y44.4966.546+37.950
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Ascentage Pharma Group International.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Ascentage is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.26 means the company has $1.26 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ascentage Pharma Group International:

  • The MRQ is 1.264. The company is just able to pay all its short-term debts.
  • The TTM is 1.264. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.264TTM1.2640.000
TTM1.264YOY1.439-0.175
TTM1.2645Y4.068-2.804
5Y4.06810Y5.048-0.980
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2643.659-2.395
TTM1.2643.834-2.570
YOY1.4394.141-2.702
3Y5.2044.661+0.543
5Y4.0685.756-1.688
10Y5.0486.151-1.103
4.4.3.2. Quick Ratio

Measures if Ascentage is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ascentage to the Biotechnology industry mean.
  • A Quick Ratio of 1.19 means the company can pay off $1.19 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ascentage Pharma Group International:

  • The MRQ is 1.185. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.185. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.185TTM1.1850.000
TTM1.185YOY1.324-0.139
TTM1.1855Y3.877-2.692
5Y3.87710Y5.674-1.796
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1852.799-1.614
TTM1.1853.143-1.958
YOY1.3243.794-2.470
3Y4.9284.307+0.621
5Y3.8775.707-1.830
10Y5.6746.457-0.783
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Ascentage Pharma Group International.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Ascentage assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ascentage to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.90 means that Ascentage assets are financed with 89.5% credit (debt) and the remaining percentage (100% - 89.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ascentage Pharma Group International:

  • The MRQ is 0.895. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.895. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.895TTM0.8950.000
TTM0.895YOY0.972-0.076
TTM0.8955Y0.763+0.133
5Y0.76310Y0.905-0.143
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8950.324+0.571
TTM0.8950.347+0.548
YOY0.9720.329+0.643
3Y0.9080.340+0.568
5Y0.7630.349+0.414
10Y0.9050.379+0.526
4.5.4.2. Debt to Equity Ratio

Measures if Ascentage is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ascentage to the Biotechnology industry mean.
  • A Debt to Equity ratio of 887.1% means that company has $8.87 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ascentage Pharma Group International:

  • The MRQ is 8.871. The company is unable to pay all its debts with equity. -1
  • The TTM is 8.871. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ8.871TTM8.8710.000
TTM8.871YOY40.217-31.346
TTM8.8715Y11.488-2.617
5Y11.48810Y6.421+5.066
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.8710.379+8.492
TTM8.8710.435+8.436
YOY40.2170.412+39.805
3Y18.3380.446+17.892
5Y11.4880.460+11.028
10Y6.4210.509+5.912
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ascentage generates.

  • Above 15 is considered overpriced but always compare Ascentage to the Biotechnology industry mean.
  • A PE ratio of 0.00 means the investor is paying $0.00 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ascentage Pharma Group International:

  • The EOD is -263.858. Based on the earnings, the company is expensive. -2
  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
EOD-263.858MRQ--263.858
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-263.858-2.282-261.576
MRQ--2.062+2.062
TTM--2.541+2.541
YOY--3.722+3.722
3Y--3.754+3.754
5Y--6.100+6.100
10Y--6.653+6.653
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ascentage Pharma Group International:

  • The EOD is -788.646. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
EOD-788.646MRQ--788.646
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-788.646-3.101-785.545
MRQ--2.689+2.689
TTM--3.594+3.594
YOY--4.363+4.363
3Y--5.065+5.065
5Y--8.478+8.478
10Y--9.273+9.273
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Ascentage is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.00 means the investor is paying $0.00 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ascentage Pharma Group International:

  • The EOD is 390.195. Based on the equity, the company is expensive. -2
  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
EOD390.195MRQ-+390.195
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD390.1951.932+388.263
MRQ-1.848-1.848
TTM-2.119-2.119
YOY-2.469-2.469
3Y-2.526-2.526
5Y-3.667-3.667
10Y-4.351-4.351
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets2,617,810
Total Liabilities2,343,648
Total Stockholder Equity264,194
 As reported
Total Liabilities 2,343,648
Total Stockholder Equity+ 264,194
Total Assets = 2,617,810

Assets

Total Assets2,617,810
Total Current Assets1,474,162
Long-term Assets1,143,648
Total Current Assets
Cash And Cash Equivalents 1,236,578
Short-term Investments 47,057
Net Receivables 99,074
Other Current Assets 131,913
Total Current Assets  (as reported)1,474,162
Total Current Assets  (calculated)1,514,622
+/- 40,460
Long-term Assets
Property Plant Equipment 905,860
Goodwill 24,694
Long Term Investments 33,858
Intangible Assets 75,998
Long-term Assets Other 59,002
Long-term Assets  (as reported)1,143,648
Long-term Assets  (calculated)1,099,412
+/- 44,236

Liabilities & Shareholders' Equity

Total Current Liabilities1,166,611
Long-term Liabilities1,177,037
Total Stockholder Equity264,194
Total Current Liabilities
Short-term Debt 779,062
Short Long Term Debt 769,623
Accounts payable 91,966
Other Current Liabilities 254,737
Total Current Liabilities  (as reported)1,166,611
Total Current Liabilities  (calculated)1,895,388
+/- 728,777
Long-term Liabilities
Long term Debt 868,642
Capital Lease Obligations 30,232
Long-term Liabilities Other 6,274
Long-term Liabilities  (as reported)1,177,037
Long-term Liabilities  (calculated)905,148
+/- 271,889
Total Stockholder Equity
Common Stock214
Retained Earnings -5,770,555
Accumulated Other Comprehensive Income -510,586
Other Stockholders Equity 6,545,121
Total Stockholder Equity (as reported)264,194
Total Stockholder Equity (calculated)264,194
+/-0
Other
Capital Stock214
Cash and Short Term Investments 1,236,578
Common Stock Shares Outstanding 75,516
Current Deferred Revenue54,085
Liabilities and Stockholders Equity 2,617,810
Net Debt 431,919
Net Invested Capital 1,902,459
Net Working Capital 307,551
Property Plant and Equipment Gross 1,127,303
Short Long Term Debt Total 1,668,497



6.2. Balance Sheets Structured

Currency in CNY. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
593,341
581,664
1,229,376
1,205,050
1,731,039
2,940,060
2,830,261
2,500,393
2,617,810
2,617,8102,500,3932,830,2612,940,0601,731,0391,205,0501,229,376581,664593,341
   > Total Current Assets 
463,699
414,713
990,219
909,105
1,079,044
295,807
1,636,488
1,344,178
1,474,162
1,474,1621,344,1781,636,488295,8071,079,044909,105990,219414,713463,699
       Cash And Cash Equivalents 
294,529
14,821
957,088
878,510
1,019,979
1,706,886
1,475,639
1,069,296
1,236,578
1,236,5781,069,2961,475,6391,706,8861,019,979878,510957,08814,821294,529
       Short-term Investments 
157,390
384,168
14,399
0
0
0
18,700
4,406
47,057
47,0574,40618,70000014,399384,168157,390
       Net Receivables 
8,308
7,853
5,253
2,526
480
54,127
61,489
163,540
99,074
99,074163,54061,48954,1274802,5265,2537,8538,308
       Other Current Assets 
3,483
7,896
13,479
7,037
23,158
68,192
89,912
95,175
131,913
131,91395,17589,91268,19223,1587,03713,4797,8963,483
   > Long-term Assets 
129,642
166,951
239,157
295,945
99,696
1,054,780
1,193,773
1,156,215
1,143,648
1,143,6481,156,2151,193,7731,054,78099,696295,945239,157166,951129,642
       Property Plant Equipment 
4,513
25,330
33,992
110,224
73,223
854,302
650,025
957,232
905,860
905,860957,232650,025854,30273,223110,22433,99225,3304,513
       Goodwill 
24,694
24,694
24,694
24,694
24,694
24,694
24,694
24,694
24,694
24,69424,69424,69424,69424,69424,69424,69424,69424,694
       Long Term Investments 
0
0
0
0
0
0
18,531
18,949
33,858
33,85818,94918,531000000
       Intangible Assets 
87,129
80,709
108,528
104,310
97,393
60,411
84,304
85,446
75,998
75,99885,44684,30460,41197,393104,310108,52880,70987,129
       Long-term Assets Other 
13,306
36,218
71,943
56,717
82,030
63,725
361,925
10,052
59,002
59,00210,052361,92563,72582,03056,71771,94336,21813,306
> Total Liabilities 
607,947
713,461
2,240,962
314,575
884,418
1,705,323
2,421,603
2,429,761
2,343,648
2,343,6482,429,7612,421,6031,705,323884,418314,5752,240,962713,461607,947
   > Total Current Liabilities 
77,618
79,535
105,269
202,062
276,148
361,109
126,753
934,173
1,166,611
1,166,611934,173126,753361,109276,148202,062105,26979,53577,618
       Short-term Debt 
358
2,019
37,587
92,194
50,561
49,451
82,647
616,404
779,062
779,062616,40482,64749,45150,56192,19437,5872,019358
       Short Long Term Debt 
0
0
0
0
44,750
39,800
510,305
606,647
769,623
769,623606,647510,30539,80044,7500000
       Accounts payable 
156
3,822
5,081
13,084
23,361
70,861
95,559
72,445
91,966
91,96672,44595,55970,86123,36113,0845,0813,822156
       Other Current Liabilities 
78,283
75,587
61,597
56,746
196,242
237,518
210,952
217,942
254,737
254,737217,942210,952237,518196,24256,74661,59775,58778,283
   > Long-term Liabilities 
530,329
633,926
2,135,693
112,513
608,270
1,344,214
1,540,451
1,495,588
1,177,037
1,177,0371,495,5881,540,4511,344,214608,270112,5132,135,693633,926530,329
> Total Stockholder Equity
-14,606
-131,797
-1,011,586
890,475
846,621
1,234,737
408,658
60,417
264,194
264,19460,417408,6581,234,737846,621890,475-1,011,586-131,797-14,606
   Common Stock
0
0
9
142
154
178
180
197
214
214197180178154142900
   Retained Earnings Total Equity000000000
   Accumulated Other Comprehensive Income -510,586-504,461-518,514000000
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 
-14,606
-131,797
-395,832
2,986,867
3,620,604
4,791,123
5,389,210
5,948,144
6,545,121
6,545,1215,948,1445,389,2104,791,1233,620,6042,986,867-395,832-131,797-14,606



6.3. Balance Sheets

Currency in CNY. All numbers in thousands.




6.4. Cash Flows

Currency in CNY. All numbers in thousands.




6.5. Income Statements

Currency in CNY. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in CNY. All numbers in thousands.

Gross Profit (+$)
totalRevenue980,650
Cost of Revenue-29,085
Gross Profit951,565951,565
 
Operating Income (+$)
Gross Profit951,565
Operating Expense-1,321,295
Operating Income-369,730-369,730
 
Operating Expense (+$)
Research Development947,245
Selling General Administrative187,125
Selling And Marketing Expenses195,998
Operating Expense1,321,2951,330,368
 
Net Interest Income (+$)
Interest Income37,840
Interest Expense-64,455
Other Finance Cost-0
Net Interest Income-26,615
 
Pretax Income (+$)
Operating Income-369,730
Net Interest Income-26,615
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-395,255-344,205
EBIT - interestExpense = -395,255
-395,008
-340,978
Interest Expense64,455
Earnings Before Interest and Taxes (EBIT)-330,800-330,800
Earnings Before Interest and Taxes (EBITDA)-237,631
 
After tax Income (+$)
Income Before Tax-395,255
Tax Provision-10,425
Net Income From Continuing Ops-405,680-405,680
Net Income-405,433
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses1,350,380
Total Other Income/Expenses Net-25,52526,615
 

Technical Analysis of Ascentage
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ascentage. The general trend of Ascentage is BULLISH with 64.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ascentage's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (64.3%) Bearish trend (-64.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Ascentage Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ascentage Pharma Group International.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 26.55 > 26.50 > 23.06.

Know someone who trades $AAPG? Share this with them.👇

Ascentage Pharma Group International Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ascentage Pharma Group International. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 9/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ascentage Pharma Group International Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ascentage Pharma Group International. The current macd is 3.84352283.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ascentage price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Ascentage. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Ascentage price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Ascentage Pharma Group International Daily Moving Average Convergence/Divergence (MACD) ChartAscentage Pharma Group International Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ascentage Pharma Group International. The current adx is 51.29.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Ascentage shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Ascentage Pharma Group International Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ascentage Pharma Group International. The current sar is 38.37.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Ascentage Pharma Group International Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ascentage Pharma Group International. The current rsi is 79.81. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Ascentage Pharma Group International Daily Relative Strength Index (RSI) ChartAscentage Pharma Group International Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ascentage Pharma Group International. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ascentage price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Ascentage Pharma Group International Daily Stochastic Oscillator ChartAscentage Pharma Group International Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ascentage Pharma Group International. The current cci is 118.71.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Ascentage Pharma Group International Daily Commodity Channel Index (CCI) ChartAscentage Pharma Group International Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ascentage Pharma Group International. The current cmo is 64.55.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Ascentage Pharma Group International Daily Chande Momentum Oscillator (CMO) ChartAscentage Pharma Group International Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ascentage Pharma Group International. The current willr is -5.83766493.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Ascentage Pharma Group International Daily Williams %R ChartAscentage Pharma Group International Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ascentage Pharma Group International.

Ascentage Pharma Group International Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ascentage Pharma Group International. The current atr is 1.79192298.

Ascentage Pharma Group International Daily Average True Range (ATR) ChartAscentage Pharma Group International Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ascentage Pharma Group International. The current obv is 3,744,073.

Ascentage Pharma Group International Daily On-Balance Volume (OBV) ChartAscentage Pharma Group International Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ascentage Pharma Group International. The current mfi is 73.69.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Ascentage Pharma Group International Daily Money Flow Index (MFI) ChartAscentage Pharma Group International Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ascentage Pharma Group International.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-02MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Ascentage Pharma Group International Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ascentage Pharma Group International based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5079.809
Ma 20Greater thanMa 5035.238
Ma 50Greater thanMa 10029.035
Ma 100Greater thanMa 20024.311
OpenGreater thanClose41.500
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Ascentage with someone you think should read this too:
  • Are you bullish or bearish on Ascentage? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ascentage? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ascentage Pharma Group International

I send you an email if I find something interesting about Ascentage Pharma Group International.


Comments

How you think about this?

Leave a comment

Stay informed about Ascentage Pharma Group International.

Receive notifications about Ascentage Pharma Group International in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.